Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [04/11/2019 07:49 PDT] FTSV Expected to Trade Down After Bearish Patterns Develop
• [04/09/2019 07:55 PDT] FTSV Expected to Trade Up After Bullish Patterns Develop
• [04/08/2019 12:05 PDT] Forty Seven, Inc. (OTC:FTSV), Up By 100.00% ($16.49) After BUYINS.NET SqueezeTrigger Report Released on Wednesday, April 3rd 2019 at a Price of $16.490.
• [04/03/2019 10:29 PDT] FTSV SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [03/29/2019 10:30 PDT] Forty Seven, Inc. (OTC:FTSV), Up By 100.00% ($16.22) After BUYINS.NET SqueezeTrigger Report Released on Friday, March 29th 2019 at a Price of $16.220.
• [03/29/2019 10:29 PDT] FTSV SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [03/01/2019 13:02 PST] Forty Seven, Inc. (OTC:FTSV), Up By 100.00% ($15.87) After BUYINS.NET SqueezeTrigger Report Released on Friday, February 22nd 2019 at a Price of $15.870.
• [02/22/2019 11:07 PST] FTSV SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.